Literature DB >> 17089036

Relationship of the aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer.

Kouji Banno1, Megumi Yanokura, Nobuyuki Susumu, Makiko Kawaguchi, Nobumaru Hirao, Akira Hirasawa, Katsumi Tsukazaki, Daisuke Aoki.   

Abstract

Epigenetic abnormalities including the aberrant DNA hypermethylation of the promoter CpG islands play a key role in the mechanism of gene inactivation in cell carcinogenesis. To identify the genes associated with aberrant DNA hypermethylation in endometrial carcinogenesis, we studied the hypermethylation of the promoter regions of five genes: hMLH1, APC, E-cadherin, RAR-beta and p16. The frequencies of aberrant hypermethylation were 40.4% (21/52) in hMLH1, 22% (11/50) in APC, 14% (7/50) in E-cadherin, and 2.3% (1/44) in RAR-beta in endometrial cancer specimens. No aberrant DNA methylation was found in p16. In atypical endometrial hyperplasia, the frequencies of aberrant methylation were 14.3% (2/14) in hMLH1 and 7.3% (1/14) in APC, whereas normal endometrial cells showed no aberrant hypermethylation of any of the five genes. The high frequencies of the aberrant DNA hypermethylation of hMLH1, APC and E-cadherin suggest that the methylation of the DNA mismatch repair and Wnt signal-related genes may be associated with endometrial carcinogenesis.

Entities:  

Mesh:

Year:  2006        PMID: 17089036

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  24 in total

1.  Cadherins, catenins and cell cycle regulators: impact on survival in a Gynecologic Oncology Group phase II endometrial cancer trial.

Authors:  Meenakshi Singh; Kathleen M Darcy; William E Brady; Rashna Clubwala; Zachary Weber; Jon V Rittenbach; Ali Akalin; Charles W Whitney; Richard Zaino; Nilsa C Ramirez; Kimberly K Leslie
Journal:  Gynecol Oncol       Date:  2011-08-03       Impact factor: 5.482

2.  Recent findings on epigenetic gene abnormalities involved in uterine cancer.

Authors:  Megumi Yanokura; Kouji Banno; Yusuke Kobayashi; Hiroyuki Nomura; Shigenori Hayashi; Eiichiro Tominaga; Daisuke Aoki
Journal:  Mol Clin Oncol       Date:  2017-09-20

Review 3.  DNA methylation in endometrial cancer.

Authors:  Meng Hua Tao; Jo L Freudenheim
Journal:  Epigenetics       Date:  2010-08-16       Impact factor: 4.528

4.  hMLH1 promoter hypermethylation and MSI status in human endometrial carcinomas with and without metastases.

Authors:  J Bischoff; A Ignatov; A Semczuk; C Schwarzenau; T Ignatov; T Krebs; D Küster; D Przadka-Rabaniuk; A Roessner; S D Costa; R Schneider-Stock
Journal:  Clin Exp Metastasis       Date:  2012-05-03       Impact factor: 5.150

Review 5.  Genome-wide epigenetic modifications in cancer.

Authors:  Yoon Jung Park; Rainer Claus; Dieter Weichenhan; Christoph Plass
Journal:  Prog Drug Res       Date:  2011

6.  Genetics of endometrial cancers.

Authors:  Tsuyoshi Okuda; Akihiko Sekizawa; Yuditiya Purwosunu; Masaaki Nagatsuka; Miki Morioka; Masaki Hayashi; Takashi Okai
Journal:  Obstet Gynecol Int       Date:  2010-04-08

7.  Array-based profiling of the differential methylation status of CpG islands in hepatocellular carcinoma cell lines.

Authors:  Bin-Bin Liu; Dan Zheng; Yin-Kun Liu; Xiao-Nan Kang; Lu Sun; Kun Guo; Rui-Xia Sun; Jie Chen; Yan Zhao
Journal:  Oncol Lett       Date:  2010-09-01       Impact factor: 2.967

Review 8.  Malignant tumors of the uterine corpus: molecular background of their origin.

Authors:  D Brany; D Dvorska; M Nachajova; P Slavik; T Burjanivova
Journal:  Tumour Biol       Date:  2015-08-26

9.  Hypermethylation of E-cadherin in endometrial carcinoma.

Authors:  Jee Hyun Park; Byung Ick Lee; Eun Seop Song; Sung Ook Whang; Woo Young Lee; Seong Jin Cho
Journal:  J Gynecol Oncol       Date:  2008-12-29       Impact factor: 4.401

10.  DNA hypermethylation and clinicopathological features in breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study.

Authors:  Meng Hua Tao; Peter G Shields; Jing Nie; Amy Millen; Christine B Ambrosone; Stephen B Edge; Shiva S Krishnan; Catalin Marian; Bin Xie; Janet Winston; Dominica Vito; Maurizio Trevisan; Jo L Freudenheim
Journal:  Breast Cancer Res Treat       Date:  2008-05-08       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.